Hinova Pharmaceuticals Inc. (SHA: 688302), a biopharmaceutical company based in Chengdu, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its Category 1 chemical drug candidate, HP560. The molecule is being evaluated as a potential treatment for myelofibrosis, a rare bone marrow disorder.
HP560 is an in-house developed small molecule anti-tumor drug that targets the BET protein family. It works by competitively binding to the bromine domain pocket of BET family proteins, which are typically acetylated histones. This binding blocks the interaction between BET family proteins and chromatin, thereby affecting downstream gene expression. The result is the inhibition of tumor cell proliferation, which is crucial for the treatment of myelofibrosis. Preclinical data on HP560 have demonstrated promising efficacy and safety profiles, with no similar products currently approved either domestically or internationally.- Flcube.com
